Gen-Probe (Nasdaq:GPRO) shareholders enjoyed a nice pop in late April when this diagnostics company announced that it was considering a sale. Those easy gains proved short-lived, though, as the stock gave up a lot of that jump when rumors started spreading in early June that the sale process had not been going well and there was only one interested party still in the bidding. (To help you determine if a stock is popping or if the entire market is moving, read Gauging The Strength Of A Market Move.)
TUTORIAL: Investing 101

Missing the quick and low-risk payday of a buyout would certainly be disappointing to some investors, but shareholders should not be too worried about this turn of events. While it would be discouraging to consider the idea that other companies do not see a lot of must-have value in Gen-Probe's business, there are other interpretations available. All in all, it may prove to be the case that life sciences companies look back on this opportunity with regret and shareholders ultimately benefit from the ongoing independence of Gen-Probe.

Last Man Standing?
When Gen-Probe initially put itself on the block, there was the collection of usual suspects in the mix as possible bidders. Gen-Probe's partner in the blood-screening business Novartis (NYSE:NVS) was on almost everyone's list, as were names like Abbott Labs (NYSE:ABT), General Electric (NYSE:GE), and a host of life sciences players like Thermo Fisher (NYSE:TMO) and Life Technologies (Nasdaq:LIFE).

If recent rumors are to be believed, though, that list has winnowed itself down quickly. Thermo Fisher likely took itself out of any consideration with the acquisition of Dionex, and other potential buyers like Danaher (NYSE:DHR) may be on the sidelines for similar reasons (while a company like Becton Dickinson (NYSE:BDX) would have antitrust problems). All in all, if the reports are to be believed, Novartis is the only company that is in the ring with a serious bid. (To learn more on how companies are bought and sold, check out Mergers And Acquisitions: Understanding Takeovers.)

Would a Deal Make Sense?
For Novartis, there would be some solid logic to a deal for Gen-Probe. The blood-screening business that the two companies share is not high-growth, but it's profitable and reliable. Moreover, diagnostics is an area where Novartis is notably lacking. Gen-Probe would bring immediate credibility in areas like HPV testing, molecular diagnostics (MDx), and STD testing, to say nothing of the future potential of additional MDx tests and personalized medicine (developing diagnostic tests to identify patients most likely to benefit from certain medications).

Of course, there is always a "but" in these conversations, and the "but" in this case is the valuation. Novartis would have to pay a pretty rich valuation for Gen-Probe and that may test the patience of shareholders a bit too far, as Novartis arguably still needs to demonstrate that it can deliver the promised results from past deals. (To help you determine to see if the Gen-Probe is a good deal, read Equity Valuation In Good Times And Bad.)

Going It Alone Not So Bad
It is not too hard to imagine that a hang-up in the Gen-Probe sale process revolves around the above-average uncertainty in the business. Gen-Probe is in many respects a company in transition, and companies may be unwilling to pay a large premium ahead of significant events like the U.S. launch of the new Panther platform and new assays in markets like prostate cancer and HPV. By the same token, maybe buyers want more assurance that Gen-Probe has a durable competitive advantage against the likes of Hologic (Nasdaq:HOLX) and Becton.

The good news for investors, though, is that Gen-Probe has made good deals in the past and has a solid growth outlook for the next three to five years. If new product launches go to plan, the stock should do at least as well as the market and if management can deliver some upside, the stock will do even better. Better still, buyers that are nervous today may be willing to come back later and pay a higher price for a little extra certainty.

The Bottom Line
Shareholders should certainly feel some disappointment that a sale seems less likely (or at least a bidding war), but it is probably better in the long run for the company to go its own way than to sell too cheaply just to get a deal done. What's more, the world of med-tech M&A is a strange one and unexpected bidders have a way of showing up (perhaps Johnson & Johnson (NYSE:JNJ) decides it just has to revitalize its diagnostics business, for instance). All in all, while Gen-Probe is not a terrifically cheap stock today, it's a solid company worth holding as an emerging player in growth markets like molecular diagnostics. (To learn more about the world of merger and acquisitions, check out Mergers And Acquisitions: Understanding Takeovers.)

Use the Investopedia Stock Simulator to trade the stocks mentioned in this stock analysis, risk free!

Related Articles
  1. Stock Analysis

    Analyzing Altria's Return on Equity (ROE) (MO)

    Learn about Altria Group's return on equity (ROE) and analyze net profit margin, asset turnover and financial leverage to determine what is causing its high ROE.
  2. Investing

    What Investors Need to Know About Returns in 2016

    Last year wasn’t a great one for investors seeking solid returns, so here are three things we believe all investors need to know about returns in 2016.
  3. Investing News

    Icahn's Bet on Cheniere Energy: Should You Follow?

    Investing legend Carl Icahn continues to lose money on Cheniere Energy, but he's increasing his stake. Should you follow his lead?
  4. Stock Analysis

    Analyzing Google's Return on Equity (ROE) (GOOGL)

    Learn about Alphabet's return on equity. How has its ROE changed over time, how does it compare to its peers and what factors are driving ROE for the company?
  5. Investing News

    Is Buffett's Bet on Oil Right for You? (XOM, PSX)

    Oil stocks are getting trounced, but Warren Buffett still likes one of them. Should you follow the leader?
  6. Stock Analysis

    The Top 5 Micro Cap Biotechnology Stocks for 2016 (BSTC, OSIR)

    Discover some of the most promising micro-cap biotechnology stocks that investors can consider for their 2016 investment portfolio.
  7. Investing News

    Chipotle Served with Criminal Probe

    Chipotle's beat muted expectations and got a clear bill from the CDC, but it now appears that an investigation into its E.coli breakout has expanded.
  8. Stock Analysis

    Analyzing Sprint Corp's Return on Equity (ROE) (S)

    Learn about Sprint's return on equity. Find out why its ROE is negative and how asset turnover and financial leverage impact ROE relative to Sprint's peers.
  9. Stock Analysis

    Why Alphabet is the Best of the 'FANGs' for 2016

    Alphabet just impressed the street, but is it the best FANG stock?
  10. Investing News

    A 2016 Outlook: What January 2009 Can Teach Us

    January 2009 and January 2016 were similar from an investment standpoint, but from a forward-looking perspective, they were very different.
  1. How do dividends affect retained earnings?

    When a company issues a cash dividend to its shareholders, the retained earnings listed on the balance sheet are reduced ... Read Full Answer >>
  2. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  3. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  4. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  5. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>
  6. What is the difference between issued share capital and subscribed share capital?

    The difference between subscribed share capital and issued share capital is the former relates to the amount of stock for ... Read Full Answer >>
Trading Center